Won Jonghwa, Lee Ge Hyeong
Molecular Immunology Division, Mogam Biotechnology Research Institute, Gyounggi-Do, South Korea.
Int Rev Immunol. 2008 Jan-Apr;27(1-2):19-41. doi: 10.1080/08830180701798976.
Recent advances in our understanding of the mechanisms of T-cell activation, migration to inflammatory sites, and pathologic disease processes triggered the development of a wide variety of T-cell-targeted signaling inhibitors, which have different targets and modes of action. Depending on the distribution and the role of targets in disease processes, T-cell inhibitors exhibit different levels of efficacy and potential side effects. This review outlines target molecules to which T-cell inhibitors have been developed, their efficacy, and potential safety concerns of T-cell inhibitors.
我们对T细胞活化、迁移至炎症部位以及引发病理疾病过程机制的理解取得了最新进展,这推动了多种靶向T细胞的信号抑制剂的开发,这些抑制剂具有不同的靶点和作用模式。根据靶点在疾病过程中的分布和作用,T细胞抑制剂表现出不同程度的疗效和潜在副作用。本综述概述了已开发出T细胞抑制剂的靶分子、它们的疗效以及T细胞抑制剂潜在的安全性问题。